Transposon said its oral small molecule TPN-101 has been selected for testing as part of the HEALEY ALS platform trial.

Living in the moment takes a lot of practice. ALS makes the past a place to visit for short periods of time, but dwelling on the future for too long can create an unbearable fear. That’s why it’s so ...

Antidepressants that inhibit REM sleep are associated with prolonged survival in people with amyotrophic lateral sclerosis, a ...

Everyone has spaces that bring peace, and life with ALS doesn't change that, writes columnist Juliet Taylor, who shares her ...

Genetic mutations in many forms of ALS lead to early problems with the transport and function of mitochondria, a study found.

ATH-1105, an experimental oral therapy for ALS, was found to be safe and well tolerated in healthy adult volunteers in a ...

On June 2, supporters across the U.S. will recognize the legacy of legendary baseball player Lou Gehrig and his impact on ALS ...

Patients with less neuronal damage, determined by low spinal fluid pNFH, had a 48% reduction in the risk of death by adding ...

MaaT033, an experimental oral therapy that uses bacteria to restore balance in the gut, may slow ALS progression, a study ...

The FDA has cleared Brainstorm to initiate a Phase 3b clinical trial testing NurOwn (debamestrocel) in people with moderate ALS.

Columnist Kristin Neva, while enjoying an unusually busy weekend, reflects on how finding balance is crucial in her life as an ALS caregiver.

The ALS Network is supporting research using electronic health records to identify existing drugs for repurposing to slow ALS progression.